Willow Biosciences expects commercial production in early 2021
Willow has contracted an ingredient manufacturing firm to produce commercial quantities of its CBG at their European facilities.
VANCOUVER — Willow Biosciences Inc. announces that it has advanced its commercialization plan by selecting a highly-regarded contract manufacturing organization to manufacture its first cannabinoid, cannabigerol, with its first commercial scale multi-kilogram run scheduled in Q1 2021.
“Advancing to commercial-scale production is the final step in our transition to becoming a revenue generating company,” said Trevor Peters, Willow’s President and Chief Executive Officer. “Our ability to begin this important milestone ahead of expectations is a testament to our exceptional scientific and commercially minded team. We are seeing strong interest in our CBG samples and are working closely to understand the needs of potential customers.”
The Company has contracted an ingredient manufacturing firm to produce commercial quantities of its CBG at their European facilities. To further streamline the production process, Willow will run a second 500-litre pilot in December. In Q1 2021, the Company will move into large scale fermenters and expects to produce its first multi-kilogram commercial batch of CBG.
“Our customers need access to high-quality cannabinoids that are manufactured to ensure end-user safety and suitability in multiple global consumer packaged goods applications,” said Chris Speed, Willow’s Senior Vice President of Sales and Marketing. “Willow’s proprietary technology is making this possible and, in the process, helping to evolve our industry to the next phase of consumer acceptance.”